brings you the latest development in the field of oncology, as XOMA Pharmaceuticals celebrates a significant milestone. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Day One Biopharmaceuticals’ OJEMDATM (tovorafenib) for the treatment of relapsed or refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG). As a result of this approval, XOMA, the partner company, is en
XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM for Pediatric Low-Grade Glioma
Published |
Modified
CSIMarket Newsroom | CSIMarket.com
CSIMarket Newsroom | CSIMarket.com
Source for this article: Based on Xoma Corporation’s official statement
For details on how CSIMarket validates financial and corporate news, please review our
Editorial Standards & Fact-Checking Policy
.
Comments